Biopharma Firm Applies to Produce Large Quantities of Controlled Meds
Published Date: 8/11/2025
Notice
Summary
Biopharmaceutical Research Company wants to get official approval to make large amounts of certain controlled substances. This affects anyone tracking or regulating these drugs and could speed up research and development. Keep an eye out for updates on approval timing and any related fees.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Application to Bulk-Manufacture Controlled Drugs
Biopharmaceutical Research Company has applied to be registered as a bulk manufacturer of basic classes of controlled substances. This affects people and organizations that track or regulate these drugs and could speed up research and development.
Watch for Approval Timing and Fees
The notice advises stakeholders to watch for updates on approval timing and any related fees. If you are an applicant, regulator, or otherwise involved with these drugs, future notices may announce when approval happens and whether fees apply.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Previous / Next Documents
Previous: 2025-15161 — Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals
Chattem Chemicals wants to get official approval to make large amounts of certain controlled substances. This affects anyone involved in drug manufacturing and regulation, as it could change who supplies these important chemicals. Keep an eye out for updates on approvals and any new rules that might come with this change.
Next: 2025-15164 — Notice of Public Hearing and Request for Comments on the Fair Market Value and Maximum Economic Recovery for the Little Eccles Coal Lease by Application, UTU-92226, in Emery County, Utah
The Bureau of Land Management wants your thoughts on how much the coal in the Little Eccles lease in Emery County, Utah, is really worth and how much can be profitably mined. This affects local communities, coal companies, and anyone interested in land use and energy resources. Speak up soon—your comments could shape the lease’s future value and mining plans!